• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT MEDICAL MASTERS SERIES HEART VALSALVA AORTIC VALVES GRAFT; HEART-VALVE, MECHANICAL

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT MEDICAL MASTERS SERIES HEART VALSALVA AORTIC VALVES GRAFT; HEART-VALVE, MECHANICAL Back to Search Results
Model Number 25VAVGJ-515
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Atrial Fibrillation (1729); Dyspnea (1816); Hemorrhage/Bleeding (1888); Pain (1994); Pleural Effusion (2010); Tachycardia (2095); Electrolyte Imbalance (2196)
Event Date 03/07/2023
Event Type  Injury  
Manufacturer Narrative
Investigation is not yet complete.A follow-up report will be submitted with all additional relevant information.
 
Event Description
Clinical information: crd_992 - valved grafts pas.Patient site id: (b)(6), (b)(6).It was reported that on (b)(6) 2023, a 25 mm sjm masters series valsalva aortic valved graft was successfully implanted.Heparin was administered during the procedure.On the same day, the patient had bleeding that required a red blood cell, platelet, and plasma transfusion.The physician noted that every single needle hole was bleeding despite the protamine administration.Therefore, pre-emptive modified cabrol patch was created using bovine pericardium.The patch was sutured along the medial aspect of the pa, distal ascending aorta, svc, upper aspect of the right atria and right ventricle using running 4-0 stitch.Once this patching was completed, no more significant bleeding was seen.The patient also had decreased urinary output requiring lactate ringers on (b)(6)2023 and (b)(6) 2023.On (b)(6) 2023, an x-ray was performed and showed that the patient was having a left pleural effusion.The patient also had hypovolemia which required a packed red blood cell transfusion.On (b)(6) 2023, the patient had atrial fibrillation with rapid ventricular response and was treated with amiodarone and metoprolol.On (b)(6) 2023, electrocardiogram (ecg) showed continued issues trying to manage post-op atrial tachycardia.The patient's inr was slightly serotherapeutic at 3.8.When evaluated at the bedside the patient was short of breath at rest, tachycardia, no chest pain other than the incision site, and states they felt palpitations.Amiodarone and metoprolol medications were adjusted.On (b)(6) 2023, the patient underwent cardioversion to normal sinus rhythm.Later that evening the patient's rhythm transitioned to junctional followed by atrial fibrillation then to atrial tachycardia.Amiodarone intravenously was given for 24 hours and a 2nd cardioversion was completed.On (b)(6) 2023 the patient converted to sinus rhythm, then later fluctuated between junctional and atrial tachycardia but asymptomatic.The patient was discharged to home with an inr of 2.4.Due to the above events the patient required prolonged hospitalization.No additional information was reported.
 
Manufacturer Narrative
An event of bleeding, decreased urinary output, left pleural effusion, hypovolemia, atrial fibrillation and post-op atrial tachycardia was reported.A returned device assessment could not be performed as the device remains implanted and was not returned for analysis.The device history record was reviewed to ensure that each manufacturing and inspection operation was performed and that the product met all specifications.Information from the field indicated that heparin was administered during the procedure and the patient's inr at the time of discharge was 2.4.The field also indicated that the physician did not believe that the reported event was as a result of the device's performance during the procedure.Based on the information received the cause of the reported event could not be conclusively determined.There is no indication of a product quality issue with regards to manufacture, design, or labeling.
 
Event Description
N/a.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
MASTERS SERIES HEART VALSALVA AORTIC VALVES GRAFT
Type of Device
HEART-VALVE, MECHANICAL
Manufacturer (Section D)
ABBOTT MEDICAL
5050 nathan lane n
plymouth MN 55442
Manufacturer (Section G)
ST. JUDE MEDICAL PUERTO RICO, INC. REG#2648612
20 b st caguas west park
caguas 00725
*   00725
Manufacturer Contact
karen krouse
5050 nathan lane n
plymouth, MN 55442
6517565400
MDR Report Key16668744
MDR Text Key312599442
Report Number2135147-2023-01457
Device Sequence Number1
Product Code LWQ
UDI-Device Identifier05414734009492
UDI-Public05414734009492
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P810002
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Study,Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial,Followup
Report Date 04/10/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model Number25VAVGJ-515
Device Catalogue Number25VAVGJ-515
Device Lot Number31337144
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 03/09/2023
Initial Date FDA Received04/03/2023
Supplement Dates Manufacturer Received04/06/2023
Supplement Dates FDA Received04/10/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured02/19/2023
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age44 YR
Patient SexMale
Patient Weight70 KG
Patient RaceWhite
-
-